Close Menu

Ambry

The panels diagnose genetic heart disorders and are the first step in an expansion of the number of tests the firm intends to offer. 

The court today upheld a federal district court's decision to deny a motion for a preliminary injunction by Myriad and other plaintiffs against Ambry Genetics.

NEW YORK (GenomeWeb) – Ambry Genetics and its collaborators today announced a partnership to create a hereditary cancer research registry leveraging next-generation sequencing.

NEW YORK (GenomeWeb) – Ambry Genetics has chosen Kapa Biosystems' Kapa Hyper Prep Kits for Ambry's ExomeNext and ExomeNext-Rapid exome sequencing assays, the companies said this week.

NEW YORK (GenomeWeb) — After more than three years offering clinical whole exome sequencing for pediatric and adult patients suspected of having rare genetic disorders, clinicians from Columbia University Medical Center have concluded that the approach is a feasible, useful, and timely option for

NEW YORK (GenomeWeb) – Memorial Sloan Kettering along with other academic research institutions and testing labs said they will launch a registry to collect the genomic and outcomes data of patients who have consented to prospective follow up after being tested with a multi-gene hereditary cancer

A US federal district court in Utah denied Myriad Genetics and other plaintiffs a preliminary junction that would have stopped Ambry Genetics from selling competing BRCA tests, even though the court determined this may harm Myriad's business.

NEW YORK (GenomeWeb News) – A US federal district court has denied Myriad Genetics and other patent holders' request for a preliminary injunction against competitor Ambry Genetics to stop it from performing and selling tests that gauge BRCA genetic mutations.

NEW YORK (GenomeWeb News) – Myriad Genetics and other parties are suing BioReference Laboratories' GeneDx alleging infringement of patents covering BRCA1 and BRCA2 genes.

Myriad Genetics last week launched its next-generation sequencing-based hereditary cancer panel to early-access users.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.